<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jcm-09-01683-t004" orientation="portrait" position="float">
 <object-id pub-id-type="pii">jcm-09-01683-t004_Table 4</object-id>
 <label>Table 4</label>
 <caption>
  <p>Drug treatment of acute coronary syndromes and coronary artery disease—evidence and potential interactions with drugs used to treat SARS-CoV-2 infection.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Potential Interactions</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <underline>P2Y12 inhibitor</underline>:
     <list list-type="simple">
      <list-item>
       <label>-</label>
       <p>Clopidogrel</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Ticagrelor</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Prasugrel</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir–Ritonavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with lopinavir–ritonavir, diminished effect of clopidogrel, increased effect of ticagrelor [
     <xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Consider using prasugrel if no contraindications [
     <xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].
     <break/>Contraindications to prasugrel: previous intracranial hemorrhage, previous ischemic stroke or TIA, or ongoing bleeds; prasugrel is not recommended for patients &gt;75 years of age or with a body weight &lt;60 kg; or in NSTE-ACS if coronary anatomy is not known [
     <xref rid="B112-jcm-09-01683" ref-type="bibr">112</xref>].
     <break/>Contraindications for ticagrelor: previous intracranial hemorrhage or ongoing bleeds [
     <xref rid="B112-jcm-09-01683" ref-type="bibr">112</xref>].
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <underline>Aspirin</underline>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of evidence on discontinuation of aspirin in Covid-19 patients. </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-dose aspirin can be assumed to be safe as antiplatelet drug in Covid-19 patients [
     <xref rid="B103-jcm-09-01683" ref-type="bibr">103</xref>].
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <underline>Statins</underline>:
     <list list-type="simple">
      <list-item>
       <label>-</label>
       <p>Atorvastatin</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Rosuvastatin</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Lovastatin</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Simvastatin</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir–Ritonavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with lopinavir–ritonavir, increased effect of atorvastatin and rosuvastatin [
     <xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>]. 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Start at lowest possible dose of rosuvastatin and atorvastatin and titrate, otherwise use pravastatin [
     <xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <underline>Beta-blockers</underline>:
     <list list-type="simple">
      <list-item>
       <label>-</label>
       <p>Metoprolol</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Carvedilol</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Propranolol</p>
      </list-item>
      <list-item>
       <label>-</label>
       <p>Labetalol</p>
      </list-item>
     </list>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine–Hydroxychloroquine Fingolimod</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroxychloroquine has a potential role in reducing heart rate and may increase effect of beta-blockers [
     <xref rid="B105-jcm-09-01683" ref-type="bibr">105</xref>].
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with chloroquine or hydroxychloroquine, beta-blockers dose reduction may be required [
     <xref rid="B105-jcm-09-01683" ref-type="bibr">105</xref>].
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACEi/ARbs</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No human evidence establishing a link between the use of these medications with an increased risk of Covid-19 acquisition or illness severity [
     <xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>].
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abrupt withdrawal in high-risk patients, especially those who have heart failure or have had MI, may result in clinical instability and adverse outcomes [
     <xref rid="B107-jcm-09-01683" ref-type="bibr">107</xref>,
     <xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>].
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">First evidences showed decreased mortality in severe Covid-19 patients with coagulopathy [
     <xref rid="B111-jcm-09-01683" ref-type="bibr">111</xref>]. 
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Given the interactions between some antiviral drugs and OACs, low molecular weight heparins, or unfractionated heparin should be preferred over OACs [
     <xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <bold>Abbreviations</bold>: ACEi: ACE inhibitors; ARBs: angiotensin receptor blockers; Covid-19: coronavirus disease; MI: myocardial infarction; NSAIDS: nonsteroidal anti-inflammatory drugs; NSTE-ACS: acute coronary syndromes without ST-segment elevation; OACs: oral anticoagulants; TIA: transient ischemic attack.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
